Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients with MIBC who received perioperative durvalumab in NIAGARA.

Lower baseline utDNA associated with longer EFS (low vs high HR 0.65, 95% CI 0.40-1.04).

J Clin Oncol 2026;44(7_suppl):636. ASCO GU 2026. Conference abstract; not a full paper at this review.